|
1
|
Rodrigues-Braz D, Zhu L, Gélizé E, Clarin JP, Chatagnon X, Benzine Y, Rampignon P, Thouvenin A, Bourges JL, Behar-Cohen F, Zhao M. Spironolactone Eyedrop Favors Restoration of Corneal Integrity after Wound Healing in the Rat. Pharmaceuticals (Basel) 2023; 16:1446. [PMID: 37895917 PMCID: PMC10609951 DOI: 10.3390/ph16101446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 09/19/2023] [Accepted: 09/21/2023] [Indexed: 10/29/2023] Open
Abstract
Abnormal corneal wound healing can compromise corneal transparency and lead to visual impairment. Mineralocorticoid receptor antagonists (MRA) are promising candidates to promote corneal remodeling with anti-inflammatory properties and lack gluococorticoids-associated side effects. In this preclinical study, a new polymer-free hydroxypropyl-gamma-cyclodextrin-based eyedrop containing 0.1% spironolactone (SPL), a potent but non-water-soluble MRA, was investigated for its ocular surface tolerance and efficacy in a rat model of corneal wound healing. SPL eyedrops were stable for up to 9 months at 4 °C. The formulation was well-tolerated since no morphological changes or inflammatory reactions were observed in the rat cornea after multiple daily instillations over 7 days. SPL eyedrops accelerated rat corneal wound healing, reduced corneal edema and inflammation, enhanced epithelial integrity, and improved nerve regeneration, suggesting restoration of corneal homeostasis, while potassium canrenoate, an active and soluble metabolite of SPL, had no effect. SPL eyedrops could benefit patients with impaired corneal wound healing, including that secondary to glucocorticoid therapy. Repurposing known drugs with known excipients will expedite translation to the clinic.
Collapse
Affiliation(s)
- Daniela Rodrigues-Braz
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
| | - Linxin Zhu
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
| | - Emmanuelle Gélizé
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
| | | | | | | | | | - Agathe Thouvenin
- CNRS, Inserm, UTCBS, Université Paris Cité, 75006 Paris, France;
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 75005 Paris, France
| | - Jean-Louis Bourges
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
- Ophtalmopole, AP-HP, Cochin Hospital, 75014 Paris, France
| | - Francine Behar-Cohen
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
- Ophtalmopole, AP-HP, Cochin Hospital, 75014 Paris, France
- Hôpital Foch, Service D’ophtalmologie, 92150 Suresnes, France
| | - Min Zhao
- Centre de Recherche des Cordeliers, Inserm, Université Paris Cité, Sorbonne Université, 75006 Paris, France; (D.R.-B.); (L.Z.); (E.G.); (J.-L.B.); (M.Z.)
| |
Collapse
|